Society for the Advancement of Psychotherapy

Legislative Protection of Identity Variables in Mental and Behavioral Health Research

Wilson T. Trusty, Ph.DJocelyn Sze, PhDStephanie L. Budge, Ph.D.Louis G. Castonguay, Ph.D.

Wilson T. Trusty, Ph.D & 3 others

February 21, 2025

We are writing to express our grave concern regarding Executive Order [EO]14168 (regarding Gender Ideology) and Executive Order [EO] 14151 (regarding Government DEI Programs). Executive Order 14168 mandates that federal agencies stop using gender identity-related terms in all official agency business, materials, and policies. Executive Order 14151 directs the termination of all mandates, programs, and activities relating to “diversity, equity, inclusion, and accessibility.” The EOs  have the potential to severely limit scientists’ ability to study the nature, causes, and treatment of mental disorders. This restriction on scientific freedom poses a significant threat to American health and economic wellbeing.

Mental and behavioral health plays a critical role in saving lives and supporting the United States (U.S.) economy. Approximately one in five adults in the U.S. suffer from a diagnosable mental disorder, and 12 million seriously consider suicide each year (Substance Abuse and Mental Health Services Administration, 2020). This burden represents not only profound human suffering but also significant societal and economic costs. For instance, the economic toll of depression alone in the U.S. exceeds $380 billion annually in healthcare costs, lost productivity, and absenteeism (Greenberg et al., 2023). Evidence-based treatments, including psychotherapy and psychotropic medications, have been shown to reduce the likelihood of suicidal behavior (van Ballegooijen et al, 2025; Huang et al., 2022) and effectively treat conditions such as depression (Guidi & Fava, 2021). These life-saving and cost-effective interventions were developed through decades of federally-funded mental health research (e.g., Swift et al., 2021; Wilkinson et al., 2021). Continued support for research on psychotherapy and psychotropic medication is crucial for refining these treatments and strengthening America’s public health and economy.

The inclusion of identity variables in mental and behavioral health research has proven essential for developing more effective interventions. Tailoring treatments to individuals’ identities—such as gender, sexual orientation, and religion—has been shown to enhance the effectiveness of psychotherapy (Bouwhuis-Van Keulen et al., 2024; Pachankis et al., 2022). Similarly, research examining identity factors has been vital to ensuring the safety and effectiveness of psychotropic medications across diverse populations, including different racial and ethnic groups (Storosum et al., 2023). In fact, addressing patients’ identities in mental healthcare is so essential that leading mental healthcare professional organizations have developed practice guidelines for the treatment of patients who hold various backgrounds and identities, such as those with disabilities (Hanson et al., 2023), diverse national origins (American Psychiatric Association, n.d.), and culturally diverse populations (American Psychological Association, n.d.). Identity-inclusive mental and behavioral health is necessary to maintain best practices that improve treatment for all Americans.

It is important to note that while Executive Orders 14168 and 14151 do not explicitly ban the use of identity variables in federally-funded scientific research, they have impacted researchers at federal agencies (such as the U.S. Department of Veterans Affairs and the Centers for Disease Control and Prevention [CDC]) and other federally-funded institutions. Some researchers have started removing and omitting identity variables from their research due to concerns over potential noncompliance with the vague and sweeping language of these orders. In some cases this concern is not merely theoretical; a directive prohibiting the use of gender-identity variables in scientific research was sent by the CDC’s chief science officer to staff members on January 31, 2025, with the intention of bringing the CDC into compliance with Executive Order 14168 (Heidt, A, 2025). We urge lawmakers to pass clear and specific laws that explicitly protect the inclusion of identity variables in federally-funded research.

In summary, mental disorders impose a heavy toll on both the wellbeing and economic stability of Americans. Research that includes identity variables leads to more effective treatments. We urge elected officials to safeguard scientists’ ability to include identity variables—such as age, sex, gender identity, race/ethnicity, culture, national origin, religion, sexual orientation, disability, language, and socioeconomic status—in mental and behavioral health research. We call on lawmakers to introduce and support legislation that ensures these identities remain in research, advancing public health and prosperity. Restricting the study of identity variables would not only hamper basic scientific quality, but also jeopardize the health and wellbeing of Americans, regardless of their individual identities.

Sincerely,

Wilson Trusty, Ph.D.*

Jocelyn Sze, Ph.D.*

Stephanie Budge, Ph.D.*

Louis Castonguay, Ph.D.*

*Licensed psychologist and member of the Society for the Advancement of Psychotherapy

This statement has been endorsed by the Society for the Advancement of Psychotherapy (Division 29 of the American Psychological Association).

About the Authors

Wilson T. Trusty, Ph.D

Wilson T. Trusty, Ph.D

Wilson Trusty, Ph.D. (he/him) is a Research Psychologist at the Center for Collegiate Mental Health (CCMH) and a Senior Staff Psychologist at Penn State University’s student counseling center. He received his Ph.D. in Clinical Psychology from Idaho State University. Wilson's research focuses on psychotherapy process and outcome, college student mental health, and intersections of college counseling center services with student academic success. His clinical specialty is trauma-informed care, and he also owns a solo private practice focused on adult Autism assessment.

Jocelyn Sze, PhD

Jocelyn Sze, PhD

Jocelyn Sze, Ph.D. is a licensed psychologist who specializes in the cognitive behavioral treatment of PTSD, anxiety, and insomnia. She is an Assistant Clinical Professor at University of California, Berkeley, where she is passionate about providing clinical training in culturally responsive evidence-based psychotherapy. Her research interests include the psychophysiology of emotion, mindfulness-based interventions, and the dissemination of basic science into guiding clinical work.

Stephanie L. Budge, Ph.D.

Stephanie L. Budge, Ph.D.

Stephanie Budge is a professor in Counseling Psychology at the University of Wisconsin-Madison, where she is the Director of Clinical Training for the doctoral program and also facilitates the Trans CARE Collaborative. Her research focuses on access to mental health care for Two Spirit, trangender, and nonbinary people, as well as investigating the effectiveness of psychotherapy interventions to focus on healing related to experiences of oppression.

Louis G. Castonguay, Ph.D.

Louis G. Castonguay, Ph.D.

Louis Castonguay is Liberal Arts Professor of Psychology at The Pennsylvania State University. His research focuses on factors related to the process, outcome, and training of psychotherapy. Over the last several years, he has been involved in the development of practice-research networks and has conducted practice-oriented research aimed at better understanding and improving psychotherapy as practice in natural settings.

References

American Psychiatric Association. (n.d.). Immigration toolkit: Displacement, trauma and mental health among migrant youth and their families. https://www.psychiatry.org/psychiatrists/diversity/education/immigration-toolkit

American Psychological Association (n.d.). Guidelines, policy statements and resolutions. https://www.apa.org/pi/oema/resources/policy

Bouwhuis-Van Keulen, A. J., Koelen, J., Eurelings-Bontekoe, L., Hoekstra-Oomen, C., & Glas, G. (2024). The evaluation of religious and spirituality-based therapy compared to standard treatment in mental health care: A multi-level meta-analysis of randomized controlled trials. Psychotherapy Research, 34(3), 339–352. https://doi.org/10.1080/10503307.2023.2241626

Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S. Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A. A., & Kessler, R. C. (2023). The economic burden of adults with major depressive disorder in the United States (2019). Advances in Therapy40(10), 4460-4479. https://doi.org/10.1007/s12325-023-02622-x

Guidi, J., & Fava, G. A. (2021). Sequential combination of pharmacotherapy and psychotherapy in major depressive disorder: A systematic review and meta-analysis. JAMA Psychiatry, 78(3), 261–269. https://doi.org/10.1001/jamapsychiatry.2020.3650

Hanson, S. L., Bruyere, S., Forber-Pratt, A., Reesman, J., & Sung, C. (2023). Guidelines for assessment and intervention with persons with disabilities: An executive summary. American Psychologist, 78(8), 995–1009. https://doi.org/10.1037/amp0001150

Heidt, A. (2025, February 4). ‘Mind-boggling’: US CDC orders gender-related terms cut from scientific papers. Nature. https://doi.org/10.1038/d41586-025-00367-x

Huang, X., Harris, L. M., Funsch, K. M., Fox, K. R., & Ribeiro, J. D. (2022). Efficacy of psychotropic medications on suicide and self-injury: A meta-analysis of randomized controlled trials. Translational Psychiatry12(1), 400. https://doi.org/10.1038/s41398-022-02173-9

Pachankis, J. E., Harkness, A., Maciejewski, K. R., Behari, K., Clark, K. A., McConocha, E., Winston, R., Adeyinka, O., Reynolds, J., Bränström, R., Esserman, D. A., Hatzenbuehler, M. L., & Safren, S. A. (2022). LGBQ-affirmative cognitive-behavioral therapy for young gay and bisexual men’s mental and sexual health: A three-arm randomized controlled trial. Journal of Consulting and Clinical Psychology, 90(6), 459–477. https://doi.org/10.1037/ccp0000724

Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf

Storosum, B. W., Steinz, C., Cohen, S. E., Mattila, T., van den Brink, W., Roes, K., de Haan, L., Denys, D. A. J. P., & Zantvoord, J. B. (2023). Ethnic differences in response to atypical antipsychotics in patients with schizophrenia: Individual patient data meta-analysis of randomised placebo-controlled registration trials submitted to the Dutch Medicines Evaluation Board. BJPsych Open9(2). https://pmc.ncbi.nlm.nih.gov/articles/PMC10044330/

Swift, J. K., Trusty, W. T., & Penix, E. A. (2021). The effectiveness of the Collaborative Assessment and Management of Suicidality (CAMS) compared to alternative treatment conditions: A meta-analysis. Suicide and Life-Threatening Behavior, 51(5), 882–896. https://doi.org/10.1111/sltb.12765

van Ballegooijen, W., Rawee, J., Palantza, C., Miguel, C., Harrer, M., Cristea, I., de Winter, R., Gilissen, R., Eikeleboom, M., Beekman, A., & Cuijpers, P. (2025). Suicidal ideation and suicide attempts after direct or indirect psychotherapy: A systematic review and meta-analysis. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2024.2854

Wilkinson, S. T., Trujillo Diaz, D., Rupp, Z. W., Kidambi, A., Ramirez, K. L., Flores, J. M., Avila-Quintero, V. U., Rhee, T. G., Olfson, M., & Bloch, M. H. (2022). Pharmacological and somatic treatment effects on suicide in adults: A systematic review and meta‐analysis. Depression and Anxiety39(2), 100-112. https://doi.org/10.1002/da.23222

Legislative Protection of Identity Variables in Mental and Behavioral Health Research | Society for the Advancement of Psychotherapy